Literature DB >> 20572016

MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer.

Thierry Soussi1, Dalil Hamroun, Linn Hjortsberg, Jean Michel Rubio-Nevado, Jean Louis Fournier, Christophe Béroud.   

Abstract

Analysis of the literature reporting p53 mutations shows that 8% of report display typographical mistakes with a notable increase in recent years. These errors are sometimes isolated, but in some cases, they concern several or even all mutations described in a single article. Furthermore, some works report unusual profile of p53 mutations whose accuracy is difficult to assess. To handle these problems we have developed MUT-TP53 2.0, an accurate and powerful tool that will automatically handle p53 mutations and generate tables ready for publication that will lower the risk of typographical errors. Furthermore, using functional and statistical information issued from the UMD p53 database, it allows to assess the biological activity and the likelihood of every p53 mutant. Copyright 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20572016     DOI: 10.1002/humu.21313

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  16 in total

1.  Splicing of mouse p53 pre-mRNA does not always follow the "first come, first served" principle and may be influenced by cisplatin treatment and serum starvation.

Authors:  Min Yang; Jack Wu; Si-Hung Wu; An-Ding Bi; D Joshua Liao
Journal:  Mol Biol Rep       Date:  2012-06-28       Impact factor: 2.316

2.  Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues.

Authors:  Jeffrey D Krimmel; Michael W Schmitt; Maria I Harrell; Kathy J Agnew; Scott R Kennedy; Mary J Emond; Lawrence A Loeb; Elizabeth M Swisher; Rosa Ana Risques
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-05       Impact factor: 11.205

Review 3.  The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis.

Authors:  Xiaomin Lou; Ju Zhang; Siqi Liu; Ningzhi Xu; D Joshua Liao
Journal:  Cell Cycle       Date:  2014-05-05       Impact factor: 4.534

4.  TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.

Authors:  Barbara Kantorova; Jitka Malcikova; Jana Smardova; Sarka Pavlova; Martin Trbusek; Nikola Tom; Karla Plevova; Boris Tichy; Sim Truong; Eva Diviskova; Jana Kotaskova; Alexandra Oltova; Nancy Patten; Yvona Brychtova; Michael Doubek; Jiri Mayer; Sarka Pospisilova
Journal:  Tumour Biol       Date:  2014-12-20

5.  Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.

Authors:  Laurence Lodé; Marion Eveillard; Valérie Trichet; Thierry Soussi; Soraya Wuillème; Steven Richebourg; Florence Magrangeas; Norbert Ifrah; Loïc Campion; Catherine Traullé; François Guilhot; Denis Caillot; Gérald Marit; Claire Mathiot; Thierry Facon; Michel Attal; Jean-Luc Harousseau; Philippe Moreau; Stéphane Minvielle; Hervé Avet-Loiseau
Journal:  Haematologica       Date:  2010-07-15       Impact factor: 9.941

6.  Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery.

Authors:  Peilin Dai; Xi Rao; Xi Zhang; Enming Qiu; Gang Wu; Yu Lin; Sitong Li; Zhou Li; Zhai Cai; Shuai Han
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

7.  Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.

Authors:  Weimin Wang; Ilona Kryczek; Lubomír Dostál; Heng Lin; Lijun Tan; Lili Zhao; Fujia Lu; Shuang Wei; Tomasz Maj; Dongjun Peng; Gong He; Linda Vatan; Wojciech Szeliga; Rork Kuick; Jan Kotarski; Rafał Tarkowski; Yali Dou; Ramandeep Rattan; Adnan Munkarah; J Rebecca Liu; Weiping Zou
Journal:  Cell       Date:  2016-04-28       Impact factor: 41.582

Review 8.  TP53 status and response to treatment in breast cancers.

Authors:  Mariana Varna; Guilhem Bousquet; Louis-François Plassa; Philippe Bertheau; Anne Janin
Journal:  J Biomed Biotechnol       Date:  2011-05-09

9.  Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells.

Authors:  Christophe Deben; Laurie Freire Boullosa; Andreas Domen; An Wouters; Bart Cuypers; Kris Laukens; Filip Lardon; Patrick Pauwels
Journal:  Cancer Drug Resist       Date:  2021-03-19

10.  Switch of FANCL, a key FA-BRCA component, between tumor suppressor and promoter by alternative splicing.

Authors:  Chengfu Yuan; Ningzhi Xu; Joshua Liao
Journal:  Cell Cycle       Date:  2012-08-23       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.